UK Markets close in 8 hrs 14 mins

Vaxart, Inc. (VXRT)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
8.19+0.11 (+1.36%)
At close: 4:00PM EDT
Sign in to post a message.
  • A
    All-in
    It’s Time to Start Thinking Seriously About Vaxart
    While risky, VXRT stock has a uniqueness to its name
    8h ago · By Josh Enomoto, InvestorPlace Contributor
    "For one thing, the longer Covid lingers, the more opportunities a tablet vaccine has to meet demand. Given the vitriolic nature of contemporary American politics, it’s unlikely that logic and reasoning will get folks to take the jab, whether that’s based in mRNA, subunit or viral-vector technology. But a tablet? That’s more palatable.
    In addition, should the crisis worsen, the federal government could potentially distribute vaccine pills to people’s mailboxes, in light of the shortage of medical administrators.
    Most importantly, VXRT stock enjoys an international catalyst. While we Americans are blessed with the latest in medical infrastructures, other nations aren’t so lucky. That’s one of the technical risks of injection-based vaccines. They often require extensive storage demands and they could injure people if administered incorrectly.
    A pill? There’s not too much that could go wrong with that. Plus, distribution of tablets doesn’t impose nearly as much infrastructural demands."
  • C
    Chris
    Interested to hear some longs perspectives on this. I don't have a ton of money to invest, but since last year I've been lucky enough to accumulate about 12k in investing. at the moment, I'm sitting on 350 shares of Sorrento, 450 in Inovio, and about 160 here in vaxart. I don't need the money any time soon but as I'm able to put more into my investing, I'm curious what you all think should be my perspective on this stock. I'll most likely stick to this same percentage breakdown moving forward unless significant news catches my eye. any thoughts? much appreciated
  • S
    Surepick
    I'm encouraged by recent news of the advisory boards and leasing of additional retail space. It's an indication that positive things are being planned for and preparations being made. I increased my position yesterday by about 10%, it'll probably be my last buy until there are solid and promising updates on where they are with COVID and Norovirus trials. That's where the meat is, the rest is window dressing without it. Vaxart has the science for a pill vaccine and the VAAST platform to deliver it, no question. Expecting updates on COVID, Norivirus, and anything else pertinent (funding??) soon.
  • S
    Surepick
    Per this afternoon's PR:
    "SOUTH SAN FRANCISCO, Calif., Sept. 22, 2021 /PRNewswire/ -- Vaxart, Inc. (NASDAQ: VXRT), today announced that one of the company's senior scientists, Susan Johnson PhD, will present at both ID Week 2021 and the 15th Vaccine Congress. Dr. Johnson will provide an update on the development of Vaxart's COVID-19 oral vaccine candidate."

    The timing is Seot.29 thru Oct 6. That's early fall. Would be nice to coincide this with COVID phase 2 start/details. We will see, stay tuned.
  • V
    Vincenzo
    I don't believe "pandemic over in a year" as Moderna Chief Officer has just said in Zurich.
    Even with higher vaccination rates and/or third doses ONLY in rich countries.

    Standing in this situation new variants will keep emerging and such strains will be vaccine resistant.

    Only BY VACCINATING THE WORLD WE CAN DEFEAT COVID-19.

    And this can be done ONLY BY ADOPTING AN EFFICIENT PILL VACCINE!

    GO VAXART!

    #FUNDVAXART
  • J
    James
    Vaxart's manufacturing Arm just won the WEDA award. The awards ceremony was held Sept. 15, at the Edgewater Hotel in Madison. Folks in attendance stated it was a wild banquet.

    The Wisconsin Economic Development Association unveiled 2021 Community and Economic Development Award (CEDA) winners at the annual CEDA Awards ceremony that was held Sept. 15, at the Edgewater Hotel in Madison.

    The CEDA Awards was established by the Wisconsin Economic Development Association (WEDA) to recognize businesses, projects, and organizations that are making significant contributions to Wisconsin’s economy.

    “Economic developers and the businesses and entrepreneurs they work with daily are the unsung heroes of the economy. They work tirelessly to help make their communities thrive, and the CEDA Awards represent a special night where their efforts and achievements are celebrated,” said WEDA President and CEO Mary Perry. “WEDA was thrilled to partner with the Wisconsin Counties Association and the Wisconsin Economic Development Corporation to present the CEDA Awards and recognize the businesses and organizations across the state committed to advancing the economy,”

    Awards were given in the following six categories at the 2021 CEDA Awards ceremony: Business Retention and Expansion; Economic Development Initiative; Economic Driver; Public Private Partnership; Real Estate Redevelopment and Reuse; and Talent Attraction.

    Business Retention & Expansion – This award honors innovative economic development projects where communities have successfully mobilized to help retain and potentially expand the operations of an existing business critical to the economic vitality of the community.

    Winner: Attwill Medical Solutions – Attwill is a life science manufacturing company bringing critical manufacturing back to central Wisconsin. Founded in Lodi, in 2017, the company produces a wide range of products such as rapid COVID tests, second-generation COVID vaccines, and innovative pharmaceuticals and medical devices. Throughout the COVID-19 pandemic, Attwill added to its staff at a time of hiring freezes across the country and halted its traditional production to produce hand sanitizer to help protect frontline workers during the pandemic. Attwill intends to further increase its position in Wisconsin’s manufacturing and biotechnology industries.
  • A
    All-in
    * Justification of being longs *
    9/21/2021: $8.08
    1/4/2021: $6.33
    1/4/2020: $2.87
    1/4/2019: $0.75

    2021 gain: 28% in 9 months
    Gain since 2020: 182% in 1 yr. 9 months
    Gain since 2019: 977% in 2 yrs. 9 months

    This means that,
    if I invested $10,000 in JAN 2021, it's worth $12,800,
    if I invested $10,000 in JAN 2020, it's worth $28,200, and
    if I invested $10,000 in JAN 2021, it's worth $107,700 now.

    Now, that's the real power of being long!
  • G
    George
    Anonymous and Mark are one and the same

    Mark1 hour ago
    Chart setting up for a bump up to $9

    ReplyReplies (3)53
    George
    Leave a reply

    GuidelinesReply
    Anonymous
    Anonymous37 minutes ago
    @George Learn the charts George. I didn't say today

    Reply
    George
    George44 seconds ago
    @Anonymous ahh so Youre Mark eh? Duly noted

    Reply
    George
    George54 minutes ago
    litterally NOTHING about the chart suggests that. You just want 9. the chart suggests a full day of nothing but swing trading.

    Reply
  • A
    All-in
    It is generally recommended that companies should consider creating an advisory board when they
    1. are crossing a developmental stage border,
    2. are experiencing rapid growth,
    3. want to build strategic partnerships, and
    4. want to raise funds.
  • B
    Body_Mind_Soul
    At IDWeek 2021:
    Poster Session: COVID-19 Vaccines
    589 - Oral Tablet Vaccination Induces Heightened Cross-Reactive CD8 T Cell Responses to SARS-COV-2 in Humans

    Background:
    Covid-19 has accelerated global demand for easily distributed vaccines. Furthermore, as variant SARS-CoV-2 strains that circumvent antibody responses emerge, cross-protective vaccines provide substantial public health benefits. Vaxart is developing a shelf stable oral tablet vaccine that incorporates both the spike (S) and the more conserved nucleocapsid (N) proteins. Vaxart’s vaccine platform uses a non-replicating adenovirus and a TLR3 agonist as an adjuvant.

    Methods:
    In an open-label phase 1 clinical study, 35 healthy subjects received either a single low (1x1010 IU; n=15) or high (5x1010 IU; n=15) dose of the vaccine candidate VXA-CoV2-1 with a small cohort receiving 2 low doses. PBMCs were taken at pre- and 7 days post-vaccination and restimulated with S and N peptides from SARS-CoV-2 or the 4 human endemic coronaviruses (HCoV). Cells were stained for CD4/CD8/CD107a (surface) and IFNg/TNFa (intracellular). Subjects that received an intramuscular (i.m.) mRNA vaccine had PBMCs taken at the same timepoints and were compared in the same assay.

    Results:
    The study’s results indicate that the VXA-CoV2-1 tablet was well tolerated. The majority of subjects had an increase in S-specific anti-viral CD8+ T cell responses. 19/26 (73%) subjects had a measurable CD8+ T cell response on day 8 above baseline, on average 1.5-4.6%. In a comparator experiment with the 2 SARS-CoV-2 i.m. mRNA vaccines, VXA-CoV2-1 outperformed other vaccine candidates with a >3.5-fold increase in S specific antiviral CD8 T cell responses. T cell responses specific to the 4 endemic HCoV were increased by 0.6% in subjects given VXA-CoV2-1.

    Conclusion: Here we describe a room temperature stable tablet that induces SARS-CoV-2 S specific CD8 T cells of high magnitude after one dose in humans. Overall, the level of antiviral SARS-CoV-2 specific T cells, particularly IFNg-producing CD8s, induced following oral immunization with VXA-CoV2-1 are of higher magnitude than the mRNA vaccines currently in use against COVID-19. T cell responses against 4 endemic HCoV were also induced. Because T cells may be important in protecting against death and severe infection, these results suggest that VXA-CoV2-1 could be cross-protective against a wide array of emerging pandemic coronaviruses.

    Presenting Author(s)
    Susan Johnson
  • s
    styx
    We now have TWO masterfully-crafted advisory boards to guide Vaxart through research phases & manufacturing/production phases. Still no funding (but can dilute shareholders to pay the board-members, per our recent filing). We have missed several projected trial dates, but the experience-level of advisors we've retained is high, so maybe that will excuse our delays. This appears to be a very-forward-looking assembling of advisors. Investors will just have to wait-and-see... that's what investors deserve, right?
  • D
    David Disano
    Ive been saying this for a lonnnnnng time.
    This will not end soon and it wont be pretty.
    Those of you who thought we'd have this under control in 2 weeks, its just a cold, its all hype, resist getting the shot are all in for a rude awakening.
    Its going to get worse.
    Current vaccines are a bandaid when a tourniquet is needed.
    This wont be over till Vaxart pill form of the vaccine is dispensed to the world.
    I said this many months ago and im repeating them.
    Mark my words.
  • E
    EdC
    Do the math...

    Pfizer
    Pfizer's latest earnings report notes that Comirnaty profits are split 50-50 with BioNTech. The companies expect the vaccine to bring in revenues of approximately $15 billion in 2021. Pfizer and BioNTech plan to supply up to 1.3 billion doses of the vaccine worldwide by the end of 2021. The vaccine, which requires two doses, costs $39 in the United States and £28 in the EU.

    Moderna
    Moderna has reached an agreement with the United States for 300 million doses, with the option to purchase an additional 200 million doses. In addition, the company reached agreements with the European Union (310 million doses with option to purchase an additional 150 million doses in 2022), Japan (50 million doses), Canada (44 million doses), the Republic of Korea (40 million doses), the United Kingdom (17 million doses), Switzerland (13.5 million doses), Colombia (10 million doses), Israel (6 million doses) and Taiwan (5 million doses).
    Moderna charges $30 for the required two shots in the U.S. and $36 in the E.U.

    J&J
    The company is on track to produce 1 billion doses for global distribution by the end of 2021, which would generate up to $10 billion. In August, Johnson & Johnson reached a more than $1 billion agreement with the United States for 100 million doses of its vaccine, with the option to purchase an additional 200 million doses, for $10 per shot. In addition, Johnson & Johnson reached an agreement with the E.U. for up to 400 million doses.

    (Credit Lucas Manfredi FOXBusiness)

    With that much at stake one could envision FDA stonewalling, arson at VXRT/manuf. partner facilities if approved. Or simply any of the 3 using their pocket change to buy and squash VXRT.
  • X
    X
    Ok so it looks like all the boards, planning , FDA approval, manufactories and distributors are all setup.. Phase 2 better be before end of month.

    But something is weird, the company looks like it is planning to commercialize a pill before even phase 2 is started... Does that mean they have extreme confidence in the sciences and maybe they will get a phase 2/3 combined or expecting a fast EUA after phase 2 blowout data?
    I dont get it! I mean all they needed is a few thousand pills.
    But they seem to be putting the structure in effect for mass production before phase 2.
  • A
    All-in
    Short % of Shares Outstanding (Aug 31, 2021): 14.16%
    This number used to be 30%+ a several months ago.
    Apparently, a note went out to all shorts, but some don't know how to read. lol
  • B
    Body_Mind_Soul
    In a comparator experiment with the 2 SARS-CoV-2 i.m. mRNA vaccines, VXA-CoV2-1 outperformed other vaccine candidates with a >3.5-fold increase in S specific antiviral CD8 T cell responses.

    Overall, the level of antiviral SARS-CoV-2 specific T cells, particularly IFNg-producing CD8s, induced following oral immunization with VXA-CoV2-1 are of higher magnitude than the mRNA vaccines currently in use against COVID-19.
  • I
    Iowa Joey
    15th Vaccine Congress: October 4, 2021 – October 6, 2021

    Dr. Johnson's Presentation Title: A room temperature-stable, tablet-based SARS-COV-2 oral vaccine candidate induces both antigen-specific mucosal IgA responses and CD8+ T cell responses in humans
    Session Name: Breakout Session 09 - Vaccines against SARS-CoV-2
    Date: 10/5/2021
    Time: 06:00:00 AM-06:15:00 AM Eastern
    Presentation Duration: 15 minutes including Q&A
  • I
    Iowa Joey
    Sep 8.5 calls are seeing interest with 7290 contracts trading vs. open int of 540, pushing implied vol up around 9 points to ~96%. Co is expected to report earnings results in early November.
  • A
    All-in
    The six leaders joining Vaxart's COVID-19 Manufacturing and Quality Advisory Board are:

    - John Aunins, Ph.D., Senior Advisor  
    Former Vice President & Chief Technology Officer, Seres Therapeutics, President Janis Biologics  

    - John Carpenter, Ph.D., Professor  
    University of Colorado School of Pharmacy, Co-Founder and Co-Director     

    - Benjamin Del Tito, Ph.D., President
    Del Tito Consulting, LLC, Senior Affiliate Consultant , Biologics Consulting  

    - Vijay Jethwa, Ph.D., Senior Consultant
    Biologics Consulting  

    - Robert Schiff, Ph.D., Founder & CEO 
    Schiff & Company, Inc., Clifford Siporin, Ph.D., Founder  
    Greystone Pharmaceutical Consulting, Inc.
  • S
    Surepick
    POTUS pledging to vaccinate 70% of the world next year. Great and lofty goal, having a shelf stable easily distributed pill could make it happen.